Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Surgery Risk Assessment Clear all
Completed Phase 2 Interventional

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

NCT00157716
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
Interventions
(MC-1) Pyridoxal-5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2006 · Synced Sep 24, 2026, 4:01 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer

NCT05540899
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Oral Cavity
Interventions
Hypofractionated Postoperative Radiotherapy
Radiation
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain

NCT00819286
View directory record Official record
Conditions
Sternal Wound Infection, Sternal Non-union, Pain, Mediastinitis
Interventions
SternaLock Rigid Fixation Plates, wire (control)
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Sacramento, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 3 Interventional

Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery

NCT06021457
View directory record Official record
Conditions
Post-Operative Complications in Cardiac Surgery
Interventions
RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Huntsville, Alabama • La Jolla, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

NCT03915470
View directory record Official record
Conditions
Staphylococcal Infections, Surgical Site Infection
Interventions
XF-73, Placebo
Drug
Lead sponsor
Destiny Pharma Plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Gainesville, Florida • Pocatello, Idaho • Des Moines, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 24, 2026, 4:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

BC Risk Assessment Before Top Surgery

NCT06239766
View directory record Official record
Conditions
Breast Cancer, Risk Reduction
Interventions
Breast Cancer Risk Assessment
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

NCT00110513
View directory record Official record
Conditions
Antithrombin III Deficiency
Interventions
Recombinant human antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eliminate Risk of Cardiac Surgical Site Events

NCT01425697
View directory record Official record
Conditions
Surgical Site Infections
Interventions
2% Chlorhexidine Gluconate cloths, Standard of Care preoperative preparation.
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
4
States / cities
Lexington, Kentucky • Ridgewood, New Jersey • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 24, 2026, 4:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Longitudinal Study Looking at the Prevalence, Risk Factors & Consequences of Persistent Post-surgical Pain in Children

NCT06354699
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
Telethon Kids Institute
Other
Eligibility
Up to 16 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 24, 2026, 4:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stanford PIPRA Validation Study in an Elderly Orthopedic Population

NCT06567574
View directory record Official record
Conditions
Delirium, Postoperative Delirium, Cognitive Impairment
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
65 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 24, 2026, 4:01 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence

NCT06862648
View directory record Official record
Conditions
Stress Urinary Incontinence (SUI)
Interventions
Acoustic Stimulation Therapy Device, Sham Acoustic Stimulation Therapy Device
Device
Lead sponsor
Acoustic Wave Cell Therapy, Inc.
Industry
Eligibility
22 Years to 77 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Phoenix, Arizona • Lakeland, Florida • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

NCT02740335
View directory record Official record
Conditions
Significant Bleeding Risk
Interventions
Octaplex, Beriplex P/N (Kcentra)
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 3 Interventional Results available

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

NCT00087022
View directory record Official record
Conditions
Kidney Cancer
Interventions
girentuximab, placebo
Biological · Other
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years to 120 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
39
States / cities
Anchorage, Alaska • Los Angeles, California • San Francisco, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

NCT01667536
View directory record Official record
Conditions
Prostate Cancer
Interventions
Drug: 99mTc-MIP-1404
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Duarte, California • Rochester, Minnesota • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 24, 2026, 4:01 PM EDT
Completed No phase listed Observational

Frailty and Muscle Strength Tests in Older Adults Undergoing Major Surgery

NCT06988176
View directory record Official record
Conditions
Frailty, Sarcopenia, Sarcopenia in Elderly, Muscle Strength, Post Operative Complications, Nutrition Assessment, Risk Assessment, Elderly (People Aged 65 or More), Hand Strength
Interventions
Frailty assessment, nutrition assessment, cognition assessment, muscle strength testing
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

NCT00118313
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim, tetanus toxoid helper peptide, dimethyl sulfoxide, imiquimod, adjuvant therapy
Biological · Drug · Procedure
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

NCT03941483
View directory record Official record
Conditions
Acute Kidney Injury (AKI)
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
35 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 24, 2026, 4:01 PM EDT
Terminated Phase 3 Interventional

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897
View directory record Official record
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 24, 2026, 4:01 PM EDT
Completed No phase listed Observational

Comparing Blood Loss, RBC Transfusions and Inflammatory Marker Changes Among Methods of CPB

NCT01083914
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

NCT02610283
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
QPI-1002, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Not applicable Interventional Results available

Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery

NCT01592708
View directory record Official record
Conditions
Post-operative Nausea, Post-operative Vomiting, Nausea Persistent
Interventions
Antiemetic anesthesia protocol
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 24, 2026, 4:01 PM EDT
Completed Not applicable Interventional Results available

The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions

NCT01450631
View directory record Official record
Conditions
Post-operative Complications, Surgical Site Infection, Surgical Wound Infection
Interventions
Prevena™ Incision Management System (PIMS), Standard-of-care Dressing
Device
Lead sponsor
KCI USA, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 24, 2026, 4:01 PM EDT
Withdrawn No phase listed Observational

Evaluation of EverOn™ System in Medical / Surgical Ward

NCT00640718
View directory record Official record
Conditions
Post Operative Patient, Patients Requiring PCA, Respiratory Patients, Patients in Risk of Fall
Interventions
Not listed
Lead sponsor
EarlySense Ltd.
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Framingham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Sep 24, 2026, 4:01 PM EDT
Not yet recruiting Phase 2 Interventional

Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG

NCT07118449
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
XC001, A195/placebo
Drug
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 24, 2026, 4:01 PM EDT